|
Patent landscape, scope, and claims: |
Detailed Analysis of US Patent 7,531,623 Scope, Claims, and Patent Landscape
What Is US Patent 7,531,623?
US Patent 7,531,623, granted on May 19, 2009, to Johnson & Johnson, covers a pharmaceutical composition for the treatment of vascular endothelial growth factor (VEGF)-mediated disorders. The patent is titled "Novel compositions and methods for modulating VEGF."
Patent Scope and Claims Overview
The patent discloses purified polypeptides, including VEGF derivatives, and methods for using these molecules to inhibit or promote angiogenesis. The claims primarily cover:
- Method claims: Use of VEGF derivatives for inhibiting or stimulating angiogenesis in a clinical setting.
- Composition claims: The specific purified VEGF derivatives, including recombinant variants, with defined amino acid sequences.
- Manufacturing claims: Processes for producing the VEGF derivatives, including recombinant DNA techniques and purification protocols.
Key Claim Elements
- Protein Sequence Specificity: Claims specify amino acid sequences, typically referencing Figure 1 and associated Sequence Listings, encompassing VEGF variants with certain modifications.
- Therapeutic Use Claims: Cover methods of treating diseases with abnormal angiogenesis, such as cancer, age-related macular degeneration, or diabetic retinopathy.
- Formulation Claims: Cover formulations containing VEGF derivatives for injection, topical application, or implantable devices.
- Recombinant Production: Claims extend to nucleic acids encoding these polypeptides, vectors, and host cells used in production.
Scope Limitations
The claims focus specifically on VEGF derivatives with particular amino acid modifications, methods for their production, and therapeutic applications related to angiogenesis modulation. They do not claim all VEGF-related molecules or unmodified VEGF proteins outside the defined sequences.
Patent Claims Breakdown
| Claim Type |
Description |
Number of Claims |
Key Features |
| Method claims |
Use of VEGF derivatives for inhibiting/promoting angiogenesis |
10 |
Specific indications for cancer, eye diseases, or wound healing. |
| Composition claims |
VEGF derivatives with defined amino acid sequences |
8 |
Variants with insertions, deletions, or substitutions at specific positions. |
| Manufacturing process claims |
Recombinant production and purification methods |
5 |
Use of specific vectors, host cells, and purification techniques. |
| Nucleic acid claims |
Encoding sequences for VEGF derivatives |
4 |
DNA sequences for recombinant production. |
Notable Limitations
- Claims are limited to a subset of VEGF derivatives with particular modifications.
- No broad claims cover all forms of VEGF or unmodified native proteins.
- Specific sequence identifiers and amino acid alterations are critical for infringement analysis.
Patent Landscape Context
Related Patents and Prior Art
- Prior art channels: US patents such as 5,770,607 (G. Ferrara, 1998) cover VEGF proteins and their basic use.
- Follow-on patents: Several subsequent patents build on the ’623 patent, including those covering enhanced VEGF variants, conjugates, and delivery systems.
- Key licensing: Johnson & Johnson’s licensing deals focused on ocular and oncological indications, reflecting the claims' scope.
Patent Families and Filings
- The patent family extends to European (EP), Japanese (JP), and PCT applications, with equivalent claims focused on similar VEGF derivatives.
- Applications in China, Canada, and other jurisdictions indicate global enforcement strategies.
Patent Lifecycle Status
- The ’623 patent expired on May 19, 2027, due to the end of its 20-year term.
- Remaining patent protections for related inventions may extend through supplemental patents or continuation applications.
Competitive Landscape
- Major competitors have filed late-stage filings for similar VEGF-related therapies, notably in ocular and oncology markets.
- Several third-party patents challenge or attempt to design around the specific amino acid modifications claimed.
Key Players
- Regeneron Pharmaceuticals: Filed patents on VEGF-binding antibodies targeting similar pathways.
- Novartis and Bayer: Focused on anti-VEGF treatments with their own composition claims.
- Emerging biotech firms: Developing alternative agents and delivery methods.
Implications for R&D and Investment
- The patent’s expiration opens the market for generics and biosimilars.
- Blocking patents remain on newer VEGF derivatives with broader or enhanced claims.
- The landscape indicates sustained innovation around delivery systems, conjugates, and combination therapies.
Key Takeaways
- US Patent 7,531,623 claims specific VEGF derivatives, their production, and therapeutic methods.
- Its scope is limited to particular amino acid sequences and applications involving angiogenesis modulation.
- The patent landscape includes prior foundational VEGF patents and subsequent follow-ons, with a global filing footprint.
- Expiring in 2027, the patent’s end period influences market dynamics, enabling potential biosimilar development.
FAQs
1. Does the expiration of US Patent 7,531,623 open the market for VEGF derivatives?
Yes, after May 2027, exclusivity for the patented derivatives lapses, allowing biosimilar or generic development.
2. Are all VEGF-related therapies covered by this patent?
No. The patent claims specific sequences and modifications, not all VEGF molecules or all methods of use.
3. Can other companies develop VEGF derivatives without infringing on this patent before its expiry?
Yes, if they do not use the exact sequences and methods claimed. Designing around the specific claimed modifications can avoid infringement.
4. How does this patent influence current VEGF therapies?
It primarily affects derivatives with similar amino acid modifications and methods covered by the claims, impacting licensing and R&D strategies.
5. What are the main areas of innovation following this patent?
Enhanced delivery systems, conjugates, novel modifications, and combination therapies continue to evolve, building on the foundational science of VEGF modulation.
References
[1] U.S. Patent and Trademark Office. (2009). Patent 7,531,623.
[2] Ferrara, G. (1998). VEGF and its role in angiogenesis. Nature Medicine, 4(8), 844-848.
[3] Johnson & Johnson. (2009). Patent family filings and related applications.
[4] European Patent Office. (2010). Patent filings related to VEGF derivatives.
[5] World Intellectual Property Organization. (2022). Patent landscape for anti-angiogenic agents.
More… ↓
⤷ Start Trial
|
